• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

丝裂原活化蛋白激酶相互作用激酶抑制剂在肿瘤免疫治疗中的研究进展

卜红, 周金培, 张惠斌

卜红, 周金培, 张惠斌. 丝裂原活化蛋白激酶相互作用激酶抑制剂在肿瘤免疫治疗中的研究进展[J]. 中国药科大学学报, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
引用本文: 卜红, 周金培, 张惠斌. 丝裂原活化蛋白激酶相互作用激酶抑制剂在肿瘤免疫治疗中的研究进展[J]. 中国药科大学学报, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
shu
BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
Citation: BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
shu

丝裂原活化蛋白激酶相互作用激酶抑制剂在肿瘤免疫治疗中的研究进展

  • 1.

    中国药科大学新药研究中心，南京 210009

  • 2.

    中国药科大学药物化学教研室，南京 210009

Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy

  • 1.

    Center of New Drug Research, China Pharmaceutical University, Nanjing 210009, China

  • 2.

    Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China

摘要

    摘要
  • 摘要: 随着肿瘤免疫疗法（tumor immunotherapy）的兴起，靶向免疫系统的小分子调节剂已成为研究热点，而免疫激酶作为一类研究较深入发展较成熟的靶点，受到越来越多的关注。丝裂原活化蛋白激酶（MAPK）相互作用激酶（MNKs）位于ERK和p38 MAPK信号通路的交汇点，可以在保守的丝氨酸209处特异性磷酸化真核翻译起始因子4E（eIF4E）并调节mRNA的翻译。MNKs信号通路在先天性和适应性免疫系统中起着重要作用，MNKs抑制剂在治疗肿瘤及免疫相关疾病的研究也越来越深入。本文就MNKs的结构特点、作用机制、信号转导途径及其与肿瘤的密切关系进行了总结，同时详细介绍了不同研究机构报道的 MNKs抑制剂的发展过程和临床研究进展。
    Abstract: With the rise of tumor immunotherapy, small molecule modulators targeting the immune system have become a research hotspot. As well-developed and mature targets, immunity protein kinases have attracted more and more attention. Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively and modulate the translation of mRNA. Herein we review the structural characteristics, mechanism, signaling transduction pathways and close relationship with tumors of MNKs.Meanwhile, the development process and clinical research progress of the MNKs inhibitors reported by different research institutions are introduced in detail.
    • HTML全文
    • 参考文献(65)
  • [1] . Oncoimmunology，2016，5（6）：e1149674.
    [2] Toogood PL. Small molecule immuno-oncology therapeutic agents［J］. Bioorg Med Chem Lett，2018，28（3）：319-329.
    [3] Ferguson FM，Gray NS. Kinase inhibitors：the road ahead［J］. Nat Rev Drug Discov，2018，17（5）：353-376.
    [4] Yuan XR，Wu HS，Bu H，et al. Targeting the immunity protein kinases for immuno-oncology［J］. Eur J Med Chem，2019，163：413-427.
    [5] Joshi S，Platanias LC. Mnk kinase pathway：cellular functions and biological outcomes［J］. World J Biol Chem，2014，5（3）：321-33.
    [6] Fukunaga R，Hunter T. MNK1，a new MAP kinase-activated protein kinase，isolated by a novel expression screening method for identifying protein kinase substrates［J］. Embo J，1997，16（8）：1921-1933.
    [7] Slentz-Kesler K，Moore JT，Lombard M，et al. Identification of the human Mnk2 gene （MKNK2） through protein interaction with estrogen receptor beta［J］. Genomics，2000，69（1）：63-71.
    [8] O''Loghlen A，Gonzalez VM，Pineiro D，et al. Identification and molecular characterization of Mnk1b，a splice variant of human MAP kinase-interacting kinase Mnk1［J］. Exp Cell Res，2004，299（2）：343-355.
    [9] Jauch R，Jakel S，Netter C，et al. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site［J］. Structure，2005，13（10）：1559-1568.
    [10] Hou JQ，Teo T，Sykes MJ，et al. Insights into the importance of DFD-motif and insertion I1 in stabilizing the DFD-out conformation of Mnk2 kinase［J］. ACS Med Chem Lett，2013，4（8）：736-741.
    [11] Scheper GC，Proud CG. Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation［J］？ Eur J Biochem，2002，269（22）：5350-5359.
    [12] Ramamurthy VP，Ramalingam S，Kwegyir-Afful AK，et al. Targeting of protein translation as a new treatment paradigm for prostate cancer［J］. Curr Opin Oncol，2017，29（3）：210-220.
    [13] Teo T，Yu MF，Yang YC，et al. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells［J］. Cancer Lett，2015，357（2）：612-623.
    [14] Pinto-Diez C，Garcia-Recio EM，Perez-Morgado MI，et al. Increased expression of MNK1b，the spliced isoform of MNK1，predicts poor prognosis and is associated with triple-negative breast cancer［J］. Oncotarget，2018，9（17）：13501-13516.
    [15] Chen S，Cui L，Hu Q，et al. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma［J］. Biochem Biophys Res Commun，2020，530（1）：142-148.
    [16] Hou S，Du P，Wang P，et al. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer［J］. Clin Transl Oncol，2017，19（9）：1107-1116.
    [17] Zhang W，Su X，Li S，et al. Inhibiting MNK selectively targets cervical cncer via suppressing eIF4E-mediated beta-catenin activation［J］. Am J Med Sci，2019，358（3）：227-234.
    [18] D''Abronzo LS，Ghosh PM. eIF4E phosphorylation in prostate cancer［J］. Neoplasia，2018，20（6）：563-573.
    [19] Wang XJ，Wang YK，Zhang QQ，et al. MAP kinase-interacting kinase 1 promotes proliferation and invasion of hepatocellular carcinoma and is an unfavorable prognostic biomarker［J］. Med Sci Monitor，2018，24：1759-1767.
    [20] Landon AL，Muniandy PA，Shetty AC，et al. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL［J］. Nat Commun，2014，5：5413.
    [21] Zhan Y，Guo J，Yang W，et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma［J］. J Clin Invest，2017，127（11）：4179-4192.
    [22] Joshi S，Platanias LC. Mnk kinases in cytokine signaling and regulation of cytokine responses［J］. Biomol Concepts，2015，6（1）：85.
    [23] Xu Y，Poggio M，Jin HY，et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting［J］. Nat Med，2019，25（2）：301-311.
    [24] Rowlett RM，Chrestensen CA，Nyce M，et al. MNK kinases regulate multiple TLR pathways and innate proinflammatory cytokines in macrophages［J］. Am J Physiol Gastrointest Liver Physiol，2008，294（2）：G452-9.
    [25] Moore CEJ，Pickford J，Cagampang FR，et al. MNK1 and MNK2 mediate adverse effects of high-fat feeding in distinct ways［J］. Sci Rep，2016，6：23476.
    [26] Sandeman LY，Kang WX，Wang XM，et al. Disabling MNK protein kinases promotes oxidative metabolism and protects against diet-induced obesity［J］. Mol Metab，2020，42：101054.
    [27] Tschopp C，Knauf U，Brauchle M，et al. Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies［J］. Mol Cell Biol Res Commun，2000，3（4）：205-211.
    [28] Knauf U，Tschopp C，Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2［J］. Mol Cell Biol，2001，21（16）：5500-5511.
    [29] Bain J，Plater L，Elliott M，et al. The selectivity of protein kinase inhibitors：a further update［J］. Biochem J，2007，408：297-315.
    [30] Han W，Ding Y，Xu YJ，et al. Discovery of a selective and potent inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 （MNK1/2） utilizing structure-based drug design［J］. J Med Chem，2016，59（7）：3034-3045.
    [31] Konicek BW，Stephens JR，McNulty AM，et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases［J］. Cancer Res，2011，71（5）：1849-1857.
    [32] Altman JK，Szilard A，Konicek BW，et al. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors［J］. Blood，2013，121（18）：3675-3681.
    [33] Klar U，Wortmann L，Kettschau G，et al. Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors：
    2014044691A1［P］. 2014-03-27［2021-01-21］.
    [34] Klar U，Wortmann L，Kettschau G，et al. Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases：
    2014048869A1［P］. 2014-04-03［2021-01-21］.
    [35] Wortmann L，Klar U，Kettschau G，et al. Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders：
    2014048894A1［P］. 2014-04-03［2021-01-21］.
    [36] Klar U，Kettschau G，Suelzle D，et al. Substituted pyrrolopyrimidines：
    2013174743A1［P］. 2013-11-28［2021-01-21］.
    [37] Richter A，Klar U，Kettschau G，et al.
    Benzothiadiazolamines：
    2015181104A1［P］. 2015-12-03［2021-01-21］.
    [38] Klar U，Bohlmann R，Sch?cke H，et al. Substituted dihydroimidazopyridinediones as MKNK
    1 and MKNK2 inhibitors：
    2018134148A1［P］. 2018-07-26［2021-01-21］.
    [39] Klar U，Sch?cke H，Sülzle D，et al. Substituted imidazopyridinpyrimidines：
    2018134335A1［P］. 2018-07-26［2021-01-21］.
    [40] Santag S，Siegel F，Wegner AM，et al. BAY 1143269，a novel MNK1 inhibitor，targets oncogenic protein expression and shows potent anti-tumor activity［J］. Cancer Lett，2017，390：21-29.
    [41] Austen M，Black P，Blackaby W，et al. Thienopyrimidines for pharmaceutical compositions：
    2010023181A1［P］. 2010-03-04［2021-01-21］.
    [42] Lehmann-Lintz T，Heckel A，Kley J，et al. 4-［cycloalkyloxy （hetero） arylamino］ thieno［
    2，3-d］
    pyrimidines having MNKL/MNK2 inhibiting activity for pharmaceutical compositions：
    2011104334A1［P］. 2011-09-01［2021-01-21］.
    [43] Lehmann-Lintz T，Kley J，Redemann N，et al. Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions：
    2011104337A1［P］. 2011-09-01［2021-01-21］.
    [44] Diab S，Li P，Basnet SKC，et al. Unveiling new chemical scaffolds as Mnk inhibitors［J］. Fut Med Chem，2016，8（3）：271-285.
    [45] Nacro K，Duraiswamy AJ，Chennamaneni LR. Bicyclic heterocyclic derivatives as MNK
    1 and MNK2 modulators and uses thereof：
    2013147711A1［P］. 2013-10-03［2021-01-21］.
    [46] Yang H，Chennamaneni LR，Ho MWT，et al. Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia［J］. J Med Chem，2018，61（10）：4348-4369.
    [47] Teneggi V，Novotny-Diermayr V，Yasin M，et al. First-in-human phase I study of ETC-206 an oral Mnk 1/2 kinase inhibitor in healthy volunteers［J］. Clin Pharmacol Ther，2018，103：S89-S89.
    [48] Nacro K，Chennamaneni LR，Cherian J. Heteroaryl alkyne derivatives and use thereof：
    2015108490A2［P］. 2014-01-17［2021-01-21］.
    [49] Chennamaneni LR，Nacro K. Bicyclic alkyne derivatives and uses thereof：
    2019013703A1［P］. 2019-01-17［2021-01-21］.
    [50] Cherian J，Nacro K，Poh ZY，et al. Structure-activity relationship studies of mitogen activated protein kinase interacting kinase （MNK） 1 and 2 and BCR-ABL1 inhibitors targeting chronic myeloid leukemic cells［J］. J Med Chem，2016，59（7）：3063-3078.
    [51] Reich SH，Sprengeler PA，Webber SE，et al. MNK inhibitors and methods related thereto：
    2015181104A1［P］. 2015-12-03［2021-01-21］.
    [52] Reich SH，Sprengeler PA，Chiang GG，et al. Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 （MNK1/2） inhibition［J］. J Med Chem，2018，61（8）：3516-3540.
    [53] Sprengeler PA，Reich SH，Ernst JT，et al.
    Isoindoline，azaisoindoline，
    dihydroindenone and dihydroazaindenone inhibitors of MNK1 and MNK2：
    2017075394A1［P］. 2017-05-04［2021-01-21］.
    [54] Sprengeler PA，Reich SH，Webber SE，et al. Heterocyclic compounds that inhibit the kinase activity of MNK useful for treating various cancers：
    2017087808A1［P］. 2017-05-26［2021-01-21］.
    [55] Webster K，Sharma R，Chiang G. Methods and compositions for cellular immunotherapy：
    2018218038A1［P］.2018-11-29［2021-01-21］.
    [56] Ernst JT，Sprengeler PA，Reich SH，et al. Piperidine-substituted MNK inhibitors and methods related thereto：
    2019275039A1［P］. 2019-09-12［2021-01-21］.
    [57] Sprengeler PA，Reich SH，Ernst JT，et al. Pyrrolo-，pyrazolo-，
    imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2：
    2019330216A1［P］. 2019-10-31［2021-01-21］.
    [58] Reich SH，Sprengeler PA，Webber SE，et al. Crystalline forms of Mnk inhibitors：
    2020086713A1［P］. 2020-04-30［2021-01-21］.
    [59] Rzymski T，Szajewska-Skuta M，Zarebski A，et al. Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in glioblastoma and colorectal cancer［J］. Cancer Res，2014，74（19）：755.
    [60] Kosciuczuk EM，Kar AK，Blyth GT，et al. Inhibitory effects of SEL201 in acute myeloid leukemia［J］. Oncotarget，2019，10（67）：7112-7121.
    [61] Kong XL，Zhou C，Zheng ZX. Heterocyclic compound used as MNK inhibitor：
    109020957A［P］. 2018-12-18［2021-01-21］.
    [62] Yang H，Gao D. MNK inhibitor：
    111253397A［P］. 2020-06-09［2021-01-21］.
    [63] Li B. Nitroimidazole derivatives and preparation and application thereof：
    110776492A［P］. 2020-02-11［2021-01-21］.
    [64] Chen CL，Zhang HB，Yuan XR，et al. Imidazopyridazine MNK
    1/MNK2 kinase inhibitors，preparation method therefor and use thereof：
    111978325A［P］. 2020-11-24［2021-01-21］.
    [65] Zhang HB，Chen CL，Yuan XR，et al. Imidazolopyridine type MNK
    1/MNK2 kinase inhibitor and preparation method and application thereof：
    111978317A［P］. 2020-11-24［2021-01-21］.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  255
  • HTML全文浏览量:  3
  • PDF下载量:  810
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-20
  • 修回日期:  2021-04-29
  • 刊出日期:  2021-08-24

目录

摘要
HTML全文
    参考文献(65)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：323917

    x 关闭 永久关闭